Blood test may signal when to switch breast cancer treatment earlier
NCT ID NCT05826964
First seen Jan 16, 2026 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether a blood test that detects tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic breast cancer. The goal is to see if switching therapy at the first sign of molecular progression, before symptoms or scans show change, can keep the cancer under control longer. The study involves 24 participants with ER-positive, HER2-negative metastatic breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Miami
Miami, Florida, 33136, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aromatase inhibitor (AI) or selective estrogen receptor degrader (SERD) plus a CDK4/6 inhibitor
What this could lead to
If successful, this could show that using a blood test to switch treatments earlier helps keep metastatic breast cancer under control longer than waiting for scans.
What could go wrong
This is a small, early-phase study with only 24 people, so results may not apply broadly. The approach may not improve outcomes and could lead to unnecessary treatment changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.